Randomized, Placebo-controlled, Double-blind Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Increasing Single Oral Doses of BAY1830839 in Healthy Male Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 06 Feb 2019
At a glance
- Drugs BAY 1830839 (Primary)
- Indications Diffuse large B cell lymphoma; Rheumatoid arthritis
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Bayer
- 28 Jan 2019 Planned End Date changed from 22 Mar 2019 to 15 Mar 2019.
- 28 Jan 2019 Planned primary completion date changed from 21 Jan 2019 to 31 Jan 2019.
- 28 Jan 2019 Status changed from recruiting to active, no longer recruiting.